Clinical trial

A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity

Recruiting now · Phase 2 · 2 countries · Registry ID NCT07639021

Recruiting nowPhase 2Interventional

What this study is about

The purpose of the study is to find out if NNC0662-0419 is safe and effective for treating participants living with obesity.

A promising-looking record is not the same as confirmed eligibility. The study team must review the full criteria and current recruitment status.

Basic eligibility

Age18 Years to Not listed

SexAll

Healthy volunteersNot accepted

ConditionObesity

Full registry criteria

Inclusion Criteria: * Male or female (sex assigned at birth, inclusive of all gender identities). * Age 18 years or above at the time of signing the informed consent. * Body mass index (BMI) greater than or equal to (≥) 30.0 kilogram per square meter (kg/m\^2) at screening. * Participant must have a desire and be committed to lose at least 25 percentage (%) of their body weight from randomisation. Exclusion Criteria: * Known or suspected hypersensitivity to study intervention(s) or related products. * Treatment with any medication prescribed for the indication of obesity or weight management (e.g. glucagon-like-peptide-1 (GLP-1) receptor agonists (RA), dual GLP-1/gastric inhibitory peptide (GIP) RAs (or any other GLP-1 based treatment) or amylin analogues)) within 90 days before screening. * Glycated haemoglobin (HbA1c) ≥ 6.5% (48 Millimoles per mole \[mmol/mol\]) as measured by the central laboratory at screening. * History of type 1 or type 2 diabetes mellitus.

Treatments and study arms

NNC0662-0419

Drug

NNC0662-0419 will be administered subcutaneously.

Semaglutide

Drug

Semaglutide will be administered subcutaneously.

NNC0662-0419 Placebo

Drug

Placebo matched to NNC0662-0419 will be administered subcutaneously.

Semaglutide placebo

Drug

Placebo matched to semaglutide will be administered subcutaneously.

Primary outcomes

Number of gastrointestinal adverse eventsFrom week 0 to week 39

Measured as number of events.

Study locations

25 locations were listed when this page was built. The first 40 are shown.

Isis Clinical Res. Ctr P.S.C.🇵🇷 Guaynabo, Puerto Rico